Dublin, 25th September 2020 (GLOBE NEWSWIRE) – The report “Celiac Disease (CD) – Epidemiology Forecast – 2030” has been added to ResearchAndMarkets.com offer.
The epidemiology of the disease covered in the report provides a historical and predictive epidemiology segmented by total prevalent celiac disease (CD) population, total prevalent celiac disease (CD) population diagnosed, prevalent population diagnosed as gender specific celiac disease (CD) , Prevalent population diagnosed by type of celiac disease (CD) and age-specific celiac disease (CD) distribution in the 7MM market covering the US, EU5 countries (Germany, France, Italy, Spain and UK) and Japan by Dal 2017 to 2030.
Detailed epidemiological segmentation of celiac disease (CD)
- The total prevalent celiac population in the 7 main markets was 6,334,993 in 2017.
- The prevalent cases of celiac disease diagnosed in total 7MM in 2017 were 1,303,459 of which the highest diagnosed prevalent cases of this disease were seen in the United States, which were 661,244.
- The publisher found 238,048 and 423,196 male and female cases in the United States in 2017.
- It was found that in the United States the number of cases of classic, non-classic and subclinical was 178,536, 343,847 and 138,861, respectively, in 2017.
- In the United States, the maximum number of celiac disease cases was found in the 19-39 age group with 241,354 cases in 2017, while the lowest number of cases was found in the> 80 age group with 13,224 cases in 2017.
- In the EU5 countries, the total prevalent celiac disease population was detected in Germany at most with 738,357 cases, followed by the UK with 650,676 cases in 2017. While, the lowest number of cases was found in Spain, or 421,326 in 2017.
- In Japan, the prevalence of celiac disease was found to be 65,148 in 2017.
Highlights of the report
- Eleven-year forecast of celiac disease (CD)
- 7MM coverage
- Total prevalent population diagnosed with celiac disease (CD)
- Through several secondary sources it is quite evident that the prevalence of celiac disease (CD) is higher among females than among males.
- The publisher analyzed type-based data for celiac disease (CD). Celiac disease (CD) can be of three types based on these data, namely classical, non-classical and sub-clinical celiac disease.
- The report also includes another important segment, namely the prevalent age-specific celiac disease (CD) population, in which various age groups, such as 0-18, 19-39, 49-59, 60-79 and > 80. The prevalence of celiac disease (CD) has been found to be highest in the 19-39 age group.
- Expected to launch potential therapies, Larazotide Acetate (9 Meters Biopharma), Latiglutenase (ImmunogenX), PRV-015 (Provention Bio) and CNP-101 / TAK-101 (Cour Pharmaceuticals / Takeda), could increase market size in the coming years, witnessed by an increase in the prevalent population diagnosed with celiac disease (CD).
Answers to key questions
- What is the disease risk, burden and unmet needs of celiac disease (CD)?
- What is the historical pool of celiac disease (CD) patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan?
- What would be the expected patient pool for celiac disease (CD) at the 7MM level?
- What are the growth opportunities in the 7MM relative to the celiac disease (CD) patient population?
- Among the countries mentioned above, which country would have the highest population prevalence of celiac disease (CD) during the forecast period (2020-2030)?
- At what CAGR is the population expected to grow through 7 million during the forecast period (2020-2030)?
- Patient segmentation
- Risk and burden of disease
- Disease risk from segmentation
- Factors that drive growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain and UK)
Study period: 2017-2030
Key topics covered:
1 Key insights
2 Overview of celiac disease at a glance
3 Executive Summary of Celiac Disease (CD)
4 History and overview of the disease: celiac disease
4.2.1 Classic CD
4.2.2 Non-classic CD
4.2.3 Silent CD
4.3.1 Genetic factors
4.3.2 Environmental factors
4.6.2 Gluten, as an environmental trigger of CD
4.7 Clinical presentation
4.8.1 CD Diagnostic Tests
4.9 Biomarkers for CD
4.9.1 Genetic biomarkers in CD
4.9.2 Serological biomarkers in CD
4.10 Differential diagnosis
5 Algorithm for diagnosing CD
6 European Society for the Study of Celiac Disease (ESsCD) Diagnostic Guidelines
6.1 Recommendations on who should be tested for CD
6.2 Recommendations for serology
6.3 Recommendations for endoscopy and histopathology
6.4 Recommendations for HLA-DQ2 / 8 typing
6.5 Recommendations for other diagnostic tests
6.6 Recommendations for diagnostic confirmation
7 World Gastroenterology Organization (WGO) Diagnostic Guidelines
7.1 Recommendation for diagnosis
7.2 Recommendations for testing patients
7.2.1 Patients with clinical manifestations suggestive of CD
7.2.2 Conditions associated with an increased risk of CD
7.2.3 First degree relatives of patients with CD
7.3 Recommendations for diagnostic tests
7.3.1 Endoscopy in patients with suspected CD
7.3.2 Intestinal biopsy and histology
7.3.3 Serum antibody tests
8 Epidemiology and patient population: key findings
8.1 7 MM of total population prevalent with celiac disease
Total 8.2 MM of prevalent population diagnosed with celiac disease
9 Country Wise-Epidemiology of Celiac Disease
9.1 United States
9.1.1 Assumptions and motivations
9.1.2 Total prevalent population of celiac disease in the United States
9.1.3 Total prevalent population diagnosed with celiac disease in the United States
9.1.4 Prevalent population of celiac disease diagnosed by gender in the United States
9.1.5 Prevalent population diagnosed by specific type of celiac disease in the United States
9.1.6 Age-specific distribution of celiac disease in the United States
9.2 EU5 countries
For more information on this report, please visit https://www.researchandmarkets.com/r/x7f3u3
Research and Markets also offers personalized research services that provide targeted, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900